Abnormal liver tests and non-alcoholic fatty liver disease predict disease progression and outcome of patients with Covid-19.
Fiche publication
Date publication
février 2022
Journal
Clinics and research in hepatology and gastroenterology
Auteurs
Membres identifiés du Cancéropôle Est :
Pr BAUMERT Thomas, Pr MUTTER Didier
Tous les auteurs :
Tripon S, Bilbault P, Fabacher T, Lefebvre N, Lescuyer S, Andres E, Schmitt E, Garnier-Kepka S, Borgne PL, Muller J, Merdji H, Chaffraix F, Mutter D, Baumert TF, Meziani F, Doffoel M
Lien Pubmed
Résumé
Coronavirus disease 2019 (COVID-19) is a serious public health issue that became rapidly pandemic. Liver injury and comorbidities, including metabolic syndrome, are associated with severe forms of the disease. This study sought to investigate liver injury, clinical features, and risk factors in patients with mild, moderate, and severe COVID-19.
Mots clés
Abbreviations, Alkaline phosphatase (ALP), COVID-19 disease, NAFLD fibrosis score (NFS), SARS-CoV-2 infection, alanine aminotransferase (ALT), aspartate aminotransferase (AST), body mass index (BMI), capillary oxygen saturation (SaO2), coronavirus disease (COVID-19), fibrosis-4 (FIB-4), gamma-glutamyl transferase (GGT), hepatic steatosis index (HSI), liver fibrosis, liver function tests (LFTs), liver steatosis, non-alcoholic fatty liver disease (NAFLD), obesity, prothrombin time (TP), severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2), total bilirubin (TBIL), upper limit of the normal (ULN)
Référence
Clin Res Hepatol Gastroenterol. 2022 Feb 25;:101894